Abstract | INTRODUCTION: METHODS: Chemonaive patients with stage IIIB/IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 2 received either 500 mg/m2 of pemetrexed (day 1, every 3 weeks) for eight cycles, or the same dosage of pemetrexed for cycles 1 and 2 and then 1200 mg/m2 of gemcitabine (days 1 and 8, every 3 weeks) for cycles 3 and 4 (repeated once for a total of eight cycles). All patients were given vitamin B12 and folic acid supplementation. RESULTS: CONCLUSIONS:
|
Authors | Cesare Gridelli, Eckhard Kaukel, Vanessa Gregorc, Maria Rita Migliorino, Thomas R Müller, Christian Manegold, Adolfo Favaretto, Andrea Martoni, Orazio Caffo, Alexander Schmittel, Antonio Rossi, Francesca Russo, Patrick Peterson, María Muñoz, Martin Reck |
Journal | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(J Thorac Oncol)
Vol. 2
Issue 3
Pg. 221-9
(Mar 2007)
ISSN: 1556-1380 [Electronic] United States |
PMID | 17410045
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Glutamates
- Pemetrexed
- Deoxycytidine
- Guanine
- Gemcitabine
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Deoxycytidine
(analogs & derivatives, therapeutic use)
- Female
- Glutamates
(therapeutic use)
- Guanine
(analogs & derivatives, therapeutic use)
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Pemetrexed
- Gemcitabine
|